Freakonomics explores the structural barriers slowing Alzheimer's research

A Freakonomics podcast episode examines why Alzheimer's drug development has stalled despite decades of effort and billions in funding. The analysis points to systemic issues in how research is organized and incentivized—relevant for indie biotech makers considering where to focus innovation efforts in neurodegenerative disease.